Get the tools and support you need to best manage your eczema

  • This field is for validation purposes and should be left unchanged.

Treatment

January 17, 2017 — Biologic drugs have been making headlines as potentially promising new therapies for treating atopic dermatitis (AD). Several have shown positive results in clinical trials and one, dupilumab, is being reviewed for approval by the Food and Drug Administration (FDA) and is expected to come to market in 2017. Biologic medications are […]

Read More


December 14, 2016 — People with atopic dermatitis have a new treatment option. Today, the U.S. Food and Drug Administration approved Eucrisa (crisaborole), a topical treatment for children and adults with mild to moderate atopic dermatitis (AD). Eucrisa works differently than other topical treatments on the market. It is not a steroid or a topical […]

Read More


October 18, 2016 – For the first time in decades, new drugs and therapies that may provide real relief for anyone living with eczema are close to being available. For many, this is a time of unprecedented hope. But what if there were a way to prevent the very first flare, to stop eczema from even starting? Frustrated by […]

Read More


What you need to know August 18, 2016 — Finding a treatment that works for your eczema or atopic dermatitis (AD) symptoms can feel like an endless cycle for some people. And it’s not just about finding the right medicine, but about getting it covered by your health plan as well. It’s hard enough when […]

Read More


June 9, 2016 – On Monday, June 6, 2016 the pharmaceutical companies Regeneron and Sanofi, reported positive results for the Phase 3 the clinical trial of the new biologic drug, dupilumab, when used in conjunction with a topical corticosteroid by adults to treat moderate-to-severe atopic dermatitis (AD).

Read More


We all play an important role, especially patients, in bringing new treatments to those that need them. Research is like a relay race that scientists can only take so far, and at some point, they must hand the baton to patients to engage in clinical trials to help bring the treatment to reality. The National […]

Read More


February 10, 2016 – In January, Anacor Pharmaceuticals, Inc. announced that it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of crisaborole topical ointment, 2%.

Read More


July 10, 2015 – Eczema can be challenging any time of year. Here are some tips for managing eczema during the summer from people just like you, friends on NEA’s Facebook page.

Read More


NEA formed a Scientific Advisory Committee Task Force to conduct a systematic review of topical corticosteroid withdrawal/topical steroid addiction in patients with atopic dermatitis and other dermatoses, and created a NEA education announcement on Topical Steroid Addiction/Withdrawal.

Read More


March 10, 2015 – There seem to be three major reasons why patients seek alternative medicine for atopic dermatitis: First, we simply don’t yet have a cure for this disease. Second, we can’t yet clearly explain why this disease occurs. While doctors try hard to describe factors that play a role in atopic dermatitis, such as cytokines and inflammatory cells, we still can’t pinpoint the root of the disease. Third, the outcomes of conventional atopic dermatitis treatments are not always consistent, and sometimes they are perceived as being unsafe.

Read More